Antiretroviral therapy in adults: updated recommendations of the International AIDS Society–USA Panel CCJ Carpenter, DA Cooper, MA Fischl, JM Gatell, BG Gazzard, ... Jama 283 (3), 381-390, 2000 | 1379 | 2000 |
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel SM Hammer, JJ Eron, P Reiss, RT Schooley, MA Thompson, S Walmsley, ... Jama 300 (5), 555-570, 2008 | 1292 | 2008 |
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel MA Thompson, JA Aberg, P Cahn, JSG Montaner, G Rizzardini, A Telenti, ... Jama 304 (3), 321-333, 2010 | 1155 | 2010 |
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel SM Hammer, MS Saag, M Schechter, JSG Montaner, RT Schooley, ... Jama 296 (7), 827-843, 2006 | 1138 | 2006 |
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel PG Yeni, SM Hammer, CCJ Carpenter, DA Cooper, MA Fischl, JM Gatell, ... Jama 288 (2), 222-235, 2002 | 987 | 2002 |
Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 908 | 2008 |
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel PG Yeni, SM Hammer, MS Hirsch, MS Saag, M Schechter, CCJ Carpenter, ... Jama 292 (2), 251-265, 2004 | 741 | 2004 |
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial B Grinsztejn, BY Nguyen, C Katlama, JM Gatell, A Lazzarin, D Vittecoq, ... The Lancet 369 (9569), 1261-1269, 2007 | 715 | 2007 |
Late presentation of HIV infection: a consensus definition A Antinori, T Coenen, D Costagiola, N Dedes, M Ellefson, J Gatell, ... HIV medicine 12 (1), 61-64, 2011 | 617 | 2011 |
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 606 | 2008 |
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study E Martinez, A Mocroft, MA García-Viejo, JB Pérez-Cuevas, JL Blanco, ... The Lancet 357 (9256), 592-598, 2001 | 558 | 2001 |
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, ... Aids 24 (11), 1667-1678, 2010 | 532 | 2010 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind … F Raffi, H Jaeger, E Quiros-Roldan, H Albrecht, E Belonosova, JM Gatell, ... The Lancet infectious diseases 13 (11), 927-935, 2013 | 504 | 2013 |
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy E Martínez, JL Blanco, JA Arnaiz, JB Pérez-Cuevas, A Mocroft, A Cruceta, ... Aids 15 (10), 1261-1268, 2001 | 473 | 2001 |
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 452 | 2010 |
Guía de terapéutica antimicrobiana J Mensa, JM Gatell, G Prats, MT Jimenez de Anta ANGIOLOGIA-BARCELONA- 47, 174-174, 1995 | 444 | 1995 |
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine E Martínez, I Conget, L Lozano, R Casamitjana, JM Gatell Aids 13 (7), 805-810, 1999 | 411 | 1999 |
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV K Squires, A Lazzarin, JM Gatell, WG Powderly, V Pokrovskiy, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 36 (5), 1011-1019, 2004 | 398 | 2004 |
Beyond viral suppression of HIV–the new quality of life frontier JV Lazarus, K Safreed-Harmon, SE Barton, D Costagliola, N Dedes, ... BMC medicine 14, 1-5, 2016 | 393 | 2016 |
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection E Martínez, JA Arnaiz, D Podzamczer, D Dalmau, E Ribera, P Domingo, ... New England Journal of Medicine 349 (11), 1036-1046, 2003 | 391 | 2003 |